FI771046A - - Google Patents

Info

Publication number
FI771046A
FI771046A FI771046A FI771046A FI771046A FI 771046 A FI771046 A FI 771046A FI 771046 A FI771046 A FI 771046A FI 771046 A FI771046 A FI 771046A FI 771046 A FI771046 A FI 771046A
Authority
FI
Finland
Application number
FI771046A
Inventor
Gordon Hanley Phillipps
George Blanch Ewan
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of FI771046A publication Critical patent/FI771046A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0011Androstane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/008Ketals at position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011Unsubstituted amino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016Oximes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI771046A 1976-04-05 1977-04-04 FI771046A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB13707/76A GB1581234A (en) 1976-04-05 1976-04-05 11a - amino - 3a - hydroxysteroids

Publications (1)

Publication Number Publication Date
FI771046A true FI771046A (fi) 1977-10-06

Family

ID=10027931

Family Applications (1)

Application Number Title Priority Date Filing Date
FI771046A FI771046A (fi) 1976-04-05 1977-04-04

Country Status (19)

Country Link
JP (1) JPS52142056A (fi)
AU (1) AU517206B2 (fi)
BE (1) BE853227A (fi)
DE (1) DE2715078A1 (fi)
DK (1) DK148677A (fi)
ES (1) ES457507A1 (fi)
FI (1) FI771046A (fi)
FR (2) FR2347382A1 (fi)
GB (1) GB1581234A (fi)
IE (1) IE45276B1 (fi)
IL (1) IL51816A (fi)
IT (1) IT1073232B (fi)
LU (1) LU77064A1 (fi)
NL (1) NL7703667A (fi)
NO (1) NO771197L (fi)
NZ (1) NZ183775A (fi)
PL (1) PL197186A1 (fi)
SE (1) SE7703929L (fi)
ZA (1) ZA772029B (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044227B1 (en) * 1980-07-16 1983-08-24 Glaxo Group Limited 11-alpha-amino androstanes, pharmaceutical compositions containing them and processes for their preparation
AU541732B2 (en) * 1980-07-16 1985-01-17 Glaxo Group Limited 11a-amino-androstanes
NZ199859A (en) * 1981-03-02 1984-10-19 Glaxo Group Ltd 11alpha-amino-3beta-hydroxy-androstanes
EP0066467B1 (en) * 1981-05-29 1984-08-08 Glaxo Group Limited 11-alpha-amino-androstanes
JPS57203100A (en) * 1981-05-29 1982-12-13 Glaxo Group Ltd 11 alpha-amino-androstanes
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
FR2910002B1 (fr) * 2006-12-13 2009-01-30 Sanofi Aventis Sa Nouveau procede pour l'obtention diastereoselective d'une amine primaire chirale sur un steroide
JP2010037243A (ja) * 2008-08-04 2010-02-18 Mitsubishi Rayon Co Ltd ノルボルネンラクトンモノマーの製造方法
CN108976272B (zh) 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
NZ627781A (en) 2012-01-23 2016-10-28 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
HUE041369T2 (hu) 2013-04-17 2019-05-28 Sage Therapeutics Inc 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására
CA3199003A1 (en) * 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3235088A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
MX2017005002A (es) 2014-10-16 2018-01-23 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos del snc.
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
KR102408399B1 (ko) 2016-03-08 2022-06-13 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
IL309259A (en) 2016-07-11 2024-02-01 Sage Therapeutics Inc C17, C20 and C21 converted neuroactive steroids and methods of using them
JP7065825B2 (ja) 2016-07-11 2022-05-12 セージ セラピューティクス, インコーポレイテッド C7、c12、およびc16置換神経刺激性ステロイドおよびそれらの使用方法
BR112020012761A2 (pt) * 2017-12-22 2021-02-17 Sage Therapeutics, Inc. composições e métodos para o tratamento de distúrbios do snc
MX2021006618A (es) 2018-12-05 2021-09-23 Sage Therapeutics Inc Esteroides neuroactivos y sus metodos de uso.
MA56046A (fr) 2019-05-31 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et compositions associées
WO2020264512A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
JP2022538300A (ja) * 2019-06-27 2022-09-01 セージ セラピューティクス, インコーポレイテッド Cns障害を治療するための組成物及び方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2982775A (en) * 1957-05-06 1961-05-02 Schering Corp 11-oximino-, amino- and acylaminosteroids

Also Published As

Publication number Publication date
FR2485020A1 (fr) 1981-12-24
IT1073232B (it) 1985-04-13
IL51816A (en) 1981-09-13
GB1581234A (en) 1980-12-10
DE2715078A1 (de) 1977-10-13
IE45276B1 (en) 1982-07-28
NL7703667A (nl) 1977-10-07
SE7703929L (sv) 1978-10-27
FR2347382A1 (fr) 1977-11-04
ES457507A1 (es) 1978-03-16
PL197186A1 (pl) 1979-06-18
AU517206B2 (en) 1981-07-16
BE853227A (fr) 1977-10-04
NZ183775A (en) 1979-12-11
IE45276L (en) 1977-10-05
JPS52142056A (en) 1977-11-26
FR2347382B1 (fi) 1982-01-08
IL51816A0 (en) 1977-06-30
NO771197L (no) 1977-10-06
LU77064A1 (fi) 1979-01-18
AU2394277A (en) 1978-10-12
ZA772029B (en) 1978-11-29
DK148677A (da) 1977-10-06

Similar Documents

Publication Publication Date Title
DK142252C (fi)
DK140653C (fi)
DE2760279A1 (fi)
DK138564C (fi)
DK141392C (fi)
DK140581C (fi)
DK137650C (fi)
DK138283C (fi)
DK139459C (fi)
JPS5648105B2 (fi)
DK140167C (fi)
DK142582C (fi)
FI770786A (fi)
JPS5348003U (fi)
DK141294C (fi)
JPS5711268B2 (fi)
JPS52107022U (fi)
JPS5710196Y2 (fi)
DK139493C (fi)
JPS52119721U (fi)
JPS5363788U (fi)
JPS5411165Y2 (fi)
DK138293C (fi)
DE2637745C2 (fi)
JPS5524182Y2 (fi)

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: GLAXO LABORATORIES LIMITED